PHASE 1/2A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Platinum Resistant Epithelial Ovarian Cancer
    Advanced Or Metastatic Sclc
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Diagnosis of locally advanced/unresectable or metastatic (stage IV) breast cancer, Small Cell Lung Cancer and/or select gynecologic malignancies including ovarian cancer.
    2. ECOG PS 0 or 1.

You may not be eligible for this study if the following are true:

    1. Participants with known symptomatic brain metastases requiring steroids.
    2. Participants with any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
    3. Major surgery within 3 weeks prior to study entry and radiation therapy within 3 weeks prior to study entry.



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.